CD163 and neoplasm: In the melanoma model resistant to anti-PD-1 checkpoint therapy, Etzerodt et al. found that the specific exhaustion of CD163+ TAMs mobilized inflammatory monocytes and promoted cytotoxic T cell-mediated tumor regression [28].